IPO
Company Profile
Encore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
Founded 2017Eagan, MinnesotaEMI
Compare with
Encore Medical FAQ
- Is Encore Medical publicly traded?
- Yes. Encore Medical trades under the ticker EMI.
Coverage Timeline
newest firstAll Coverage
IPO~$12.6M-$14.67M
Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device
Encore Medical filed an amended S-1 on July 1 ahead of a planned NYSE American listing under ticker EMI, offering 3 million shares at an expected $5.00 each to raise roughly $12.6-14.67 million to fund US clinical trials for its catheter-delivered heart-defect closure device, which has completed more than 35,000 implants outside the United States but has not yet been approved for US sale. Underwriters BofA Securities, Goldman Sachs and Morgan Stanley are jointly leading the offering.
IPO
Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens
IPO$5.00/share IPO
Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens
Encore Medical, a structural heart device company developing transcatheter septal occlusion products, filed its latest S-1/A on June 30, targeting an IPO of 3 million shares at an expected $5 per share on NYSE American under ticker EMI. The company's cash balance stood at just $34,619 as of March 31, 2026, underscoring how urgently it needs the offering to fund ongoing US clinical trials.